Behera, 372 patient HCQ prophylaxis study: 28% fewer cases [p=0.29] https://c19p.org/behera
copied to clipboard
Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study
et al., PLoS ONE, doi:10.1371/journal.pone.0247163 (preprint 11/3)
Retrospective matched case-control prophylaxis study for HCQ, ivermectin, and vitamin C with 372 healthcare workers, showing lower COVID-19 incidence for all treatments, with statistical significance reached for ivermectin.HCQ OR 0.56, p = 0.29
Ivermectin OR 0.27, p < 0.001
Vitamin C OR 0.82, p = 0.58
Ivermectin OR 0.27, p < 0.001
Vitamin C OR 0.82, p = 0.58
|
risk of case, 27.9% lower, RR 0.72, p = 0.29, treatment 7 of 19 (36.8%), control 179 of 353 (50.7%), NNT 7.2, adjusted per study, odds ratio converted to relative risk, model 2 conditional logistic regression.
|
|
risk of case, 26.3% lower, RR 0.74, p = 0.25, treatment 7 of 19 (36.8%), control 179 of 353 (50.7%), NNT 7.2, odds ratio converted to relative risk, matched pair analysis.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Behera et al., 11/3/2020, retrospective, India, South Asia, peer-reviewed, 13 authors.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.